SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med. 1996; 124: 833-837.
  • 2
    Keyes M, Morris WJ, Spadinger I, et al. Radiation oncology and medical physics quality assurance in British Columbia Cancer Agency's Provincial Prostate Brachytherapy Program [published online ahead of print June 21, 2012]. Brachytherapy. 2012.
  • 3
    Morris WJ, Keyes M, Palma D, et al. Population based study of biochemical and survival outcomes after permanent 125 I brachytherapy for low- and intermediate-risk prostate cancer. Urology. 2009; 73: 860-865.
  • 4
    Morris WJ, Keyes M, Palma D, et al. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 73: 1432-1438.
  • 5
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
  • 6
    Sylvester JE, Grimm PD, Galbreath RW, et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following Iodine 125 prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys. 2011; 81: 376-381.
  • 7
    Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int. 2011; 107: 882-891.
  • 8
    Langley S, Ahmed HU, Al-Qaisieh B, et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int. 2012; 109(suppl 1): 7-16.
  • 9
    Klotz L, Zhang L, Lam A, et al. Clinical results of long term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010; 28: 126-131.
  • 10
    Van Den Bergh RCN, Vasarainen H, Van Der Poel HG, et al. Short-term outcomes of the prospective multicentre “Prostate Cancer Research International: Active Surveillance” study. Br J Urol. 2010; 105: 956-962.
  • 11
    Herbert C, Liu M, Tyldesley S, et al. Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer who have an estimated 10-year overall survival of >90%. Int J Radiat Oncol Biol Phys. 2012; 83: 22-27.
  • 12
    Morris WJ, Halperin R, Spadinger I. Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room? Brachytherapy. 2010; 9: 289-292.
  • 13
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external radiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trials. Lancet. 2002; 360: 103-106.
  • 14
    Jones CU, Hunt D, McGowan D, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011; 365: 107-118.
  • 15
    Denham WJ, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011; 12: 451-459.
  • 16
    Keating NL, O'Malley AJ, Smith MR, et al. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-4455.
  • 17
    Pickles T, Keyes M, Morris WJ. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys. 2010; 76: 43-49.
  • 18
    Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009; 74: 1405-1418.
  • 19
    Taira AV, Merrick GS, Galbreath RW, et al. Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2010; 76: 349-354.
  • 20
    Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007; 67: 327-333.
  • 21
    Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 65-70.
  • 22
    Sylvester JE, Grimm PD, Blasko JC, et al. Fifteen-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys. 2007; 67: 57-64.
  • 23
    Cesaretti JA, Stone NN, Skouteris VM, et al. Brachytherapy for the treatment of prostate cancer. Cancer J. 2007; 13: 302-312.
  • 24
    Hinnen KA, Battermann JJ, van Roermund J, et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2009; 76: 1433-1438.
  • 25
    Henry AM, Bashar AQ, Gould K, et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of Leeds 10-year single center brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010; 76: 50-56.
  • 26
    Sharkey J, Cantor A, Solc Z, et al. PD-103 brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005; 4: 35-44.
  • 27
    Giberti C, Chiono L, Gallo F, et al. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009; 27: 607-612.
  • 28
    Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results of the Prostate Cancer Results Study Group. BJU Int. 2012; 109(suppl 1): 22-29.
  • 29
    Pickles T, Morris WJ, Kattan W, et al. Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy. 2011; 10: 9-14.
  • 30
    Keyes M, Spadinger I, Liu M, et al. Rectal toxicity and rectal dosimetry in low-dose-rate I permanent prostate implant: a long term study in 1006 patients. Brachytherapy. 2012; 11: 199-208.
  • 31
    Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009; 73: 1023-1032.
  • 32
    Keyes M, Schellenberg D, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys. 2006; 64: 825-834.
  • 33
    Macdonald AG, Keyes M, Kruk A, et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important? Int J Radiat Oncol Biol Phys. 2005; 63: 155-163.